82 related articles for article (PubMed ID: 30284744)
1. RANZCOG Fellows' adherence to guidelines following cytological prediction of cervical adenocarcinoma-in-situ: Cause for concern?
Powell A; Cohen PA; Spilsbury K; Steel N; Blomfield P
Aust N Z J Obstet Gynaecol; 2019 Apr; 59(2):294-300. PubMed ID: 30284744
[TBL] [Abstract][Full Text] [Related]
2. Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins.
Munro A; Codde J; Spilsbury K; Stewart CJ; Steel N; Leung Y; Tan J; Salfinger SG; Mohan GR; Semmens JB; Cohen PA
Acta Obstet Gynecol Scand; 2017 Apr; 96(4):432-437. PubMed ID: 28181670
[TBL] [Abstract][Full Text] [Related]
3. Personalized Medicine and Cervical Screening: Development of Individualized Quantitative Risk Assessments for Cervical Adenocarcinoma and Adenocarcinoma in situ.
Jones TE; Onisko A; Austin RM
Acta Cytol; 2021; 65(2):158-164. PubMed ID: 33260179
[TBL] [Abstract][Full Text] [Related]
4. Conservative management of adenocarcinoma in situ of the cervix.
Shin CH; Schorge JO; Lee KR; Sheets EE
Gynecol Oncol; 2000 Oct; 79(1):6-10. PubMed ID: 11006022
[TBL] [Abstract][Full Text] [Related]
5. Adenocarcinoma in situ of the uterine cervix: Clinical practice guidelines from the Italian society of colposcopy and cervical pathology (SICPCV).
Ciavattini A; Giannella L; Delli Carpini G; Tsiroglou D; Sopracordevole F; Chiossi G; Di Giuseppe J;
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():273-277. PubMed ID: 31352128
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard?
Munro A; Leung Y; Spilsbury K; Stewart CJ; Semmens J; Codde J; Williams V; O'Leary P; Steel N; Cohen P
Gynecol Oncol; 2015 May; 137(2):258-63. PubMed ID: 25769659
[TBL] [Abstract][Full Text] [Related]
7. Follow-up Findings in Postconservative Treatment Surveillance for Women With Cervical Adenocarcinoma In Situ.
Upadhyay Baskota S; Wang T; Zhao C
J Low Genit Tract Dis; 2021 Jan; 25(1):38-42. PubMed ID: 33284146
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix.
Costa S; Negri G; Sideri M; Santini D; Martinelli G; Venturoli S; Pelusi C; Syrjanen S; Syrjanen K; Pelusi G
Gynecol Oncol; 2007 Jul; 106(1):170-6. PubMed ID: 17481701
[TBL] [Abstract][Full Text] [Related]
9. Conservative Treatment for Cervical Adenocarcinoma In Situ: Long-Term Results.
Monti E; Somigliana E; Alberico D; Boero V; Iorio M; Di Loreto E; Dell'acqua A; Liverani CA
J Low Genit Tract Dis; 2022 Oct; 26(4):293-297. PubMed ID: 35917498
[TBL] [Abstract][Full Text] [Related]
10. Atypical carcinoid of the uterine cervix accompanying adenocarcinoma in situ.
Ling C; Shen Y
J Clin Pathol; 2018 Nov; 71(11):1030. PubMed ID: 30154130
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of conization of the cervix in the management of cervical intraepithelial glandular neoplasia (CIGN)--a preliminary report.
Cullimore JE; Luesley DM; Rollason TP; Byrne P; Buckley CH; Anderson M; Williams DR; Waddell C; Hudson E; Shafi MI
Br J Obstet Gynaecol; 1992 Apr; 99(4):314-8. PubMed ID: 1316142
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting residual lesion in women with cervical adenocarcinoma in situ after cone excisional biopsy.
Srisomboon J; Kietpeerakool C; Suprasert P; Siriaunkgul S; Khunamornpong S; Prompittayarat W
Asian Pac J Cancer Prev; 2007; 8(2):225-8. PubMed ID: 17696736
[TBL] [Abstract][Full Text] [Related]
13. Outcome after a cytological prediction of glandular abnormality.
Mitchell HS
Aust N Z J Obstet Gynaecol; 2004 Oct; 44(5):436-40. PubMed ID: 15387866
[TBL] [Abstract][Full Text] [Related]
14. Severe cervical glandular cell lesions and severe cervical combined lesions: predictive value of the papanicolaou smear.
van Aspert-van Erp AJ; Smedts FM; Vooijs GP
Cancer; 2004 Aug; 102(4):210-7. PubMed ID: 15368312
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Management of Adenocarcinoma in Situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations.
Teoh D; Musa F; Salani R; Huh W; Jimenez E
Obstet Gynecol; 2020 Apr; 135(4):869-878. PubMed ID: 32168211
[TBL] [Abstract][Full Text] [Related]
16. Adenocarcinoma in situ of the uterine cervix.
Muntz HG; Bell DA; Lage JM; Goff BA; Feldman S; Rice LW
Obstet Gynecol; 1992 Dec; 80(6):935-9. PubMed ID: 1448263
[TBL] [Abstract][Full Text] [Related]
17. Factors predicting disease outcome in early stage adenocarcinoma of the uterine cervix.
Erzen M; Mozina A; Bertole J; Syrjänen K
Eur J Obstet Gynecol Reprod Biol; 2002 Mar; 101(2):185-91. PubMed ID: 11858896
[TBL] [Abstract][Full Text] [Related]
18. Follow-up of women with cervical cytological abnormalities showing atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion: a nationwide cohort study.
Sundström K; Lu D; Elfström KM; Wang J; Andrae B; Dillner J; Sparén P
Am J Obstet Gynecol; 2017 Jan; 216(1):48.e1-48.e15. PubMed ID: 27457115
[TBL] [Abstract][Full Text] [Related]
19. Risk for residual adenocarcinoma in situ or cervical adenocarcinoma in women undergoing loop electrosurgical excision procedure/conization for adenocarcinoma in situ.
DeSimone CP; Day ME; Dietrich CS; Tovar MM; Modesitt SC
J Reprod Med; 2011; 56(9-10):376-80. PubMed ID: 22010519
[TBL] [Abstract][Full Text] [Related]
20. Protection against squamous cell carcinoma and cervical adenocarcinoma afforded by cervical cytology screening: a cross-sectional study.
Vale DB; Braganca JF; Morais SS; Zeferino LC
Int J Gynecol Cancer; 2014 Feb; 24(2):321-8. PubMed ID: 24407579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
